首页 | 本学科首页   官方微博 | 高级检索  
     


Adjuvants Based on Hybrid Antibiotics Overcome Resistance in Pseudomonas aeruginosa and Enhance Fluoroquinolone Efficacy
Authors:Dr. Bala Kishan Gorityala  Dr. Goutam Guchhait  Dinesh M. Fernando  Soumya Deo  Prof. Sean A. McKenna  Prof. George G. Zhanel  Prof. Ayush Kumar  Prof. Frank Schweizer
Affiliation:1. Department of Chemistry, University of Manitoba, Winnipeg, MB, R3T 2N2 (Canada);2. Department of Microbiology, University of Manitoba, Winnipeg, MB, R3T 2N2 (Canada);3. Department of Biochemistry and Medical Genetics, Winnipeg, MB, R3T 2N2 (Canada);4. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, R3T 1R9 (Canada)
Abstract:The use of adjuvants that rescue antibiotics against multidrug‐resistant (MDR) pathogens is a promising combination strategy for overcoming bacterial resistance. While the combination of β‐lactam antibiotics and β‐lactamase inhibitors has been successful in restoring antibacterial efficacy in MDR bacteria, the use of adjuvants to restore fluoroquinolone efficacy in MDR Gram‐negative pathogens has been challenging. We describe tobramycin–ciprofloxacin hybrid adjuvants that rescue the activity of fluoroquinolone antibiotics against MDR and extremely drug‐resistant Pseudomonas aeruginosa isolates in vitro and enhance fluoroquinolone efficacy in vivo. Structure–activity studies reveal that the presence of both tobramycin and ciprofloxacin, which are separated by a C12 tether, is critical for the function of the adjuvant. Mechanistic studies indicate that the antibacterial modes of ciprofloxacin are retained while the role of tobramycin is limited to destabilization of the outer membrane in the hybrid.
Keywords:aminoglycosides  antibiotics  drug design  fluoroquinolones  Pseudomonas aeruginosa
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号